All News

Prevalence of Cardiovascular Disease in Rheumatoid Arthritis A prospective study of the BioSTAR registry estimates the prevalence of cardiovascular disease in rheumatoid arthritis (RA) to be 4.6%. https://t.co/NRn0DrYoBX https://t.co/qOoTmBNB1p

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2024 @RheumNow SPA spectrum Q and A 🔥 - @lihi_eder 👏advocating for #POCUS #mskus and enthesitis - we agree @CrusSurc - confirming the concept of #pocus as an extension of the clinical exam and to be kept in the hands of the clinician - doesn't seem an area yet for AI 🤖

CRUS-SURC CrusSurc ( View Tweet)

Oh, snap! But this is true, a single course rituximab at baseline and none at 6 months (or anything else) as a comparator is just wild in a 12 month trial @EBRheum @RheumNow #RNL2024 https://t.co/wuIkuLzIpg

Links:

Richard Conway RichardPAConway ( View Tweet)
A picture paints a thousand words. One of the reasons why statistical significance is not the be all and end all. I would say severe DAH is the most likely scenario I would use PLEX, more so than severe renal disease. @EBRheum @RheumNow #RNL2024 https://t.co/GHg6t4OHxf

Links:

Richard Conway RichardPAConway ( View Tweet)
Rituximab is superior to cyclophosphamide in relapsing AAV. Provided you are relapsing after having cyclophosphamide as your first agent of course... @EBRheum @RheumNow #RNL2024 https://t.co/JfbcKH2zCG

Links:

Richard Conway RichardPAConway ( View Tweet)
Does adding NSAID to TNFi help prevent radiographic progression? @LianneGensler #RNL2024 @RheumNow Adding Celecoxib to TNFi: numerically less progression, but not statistically significant https://t.co/rzuOL9q93x

Links:

Eric Dein ericdeinmd ( View Tweet)
Dr. @lihi_eder approaches enthesitis both clinically and with imaging *highly recommended. NSAIDs and local steroids may be useful with caution. Advanced tx strongly recommended if initial tx fails/other domains involved. #RNL2024 @RheumNow https://t.co/SKrWmp115M

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Vedolizumab-induced enthesitis @lihi_eder #RNL2024 @RheumNow 11/90 (12.2%) of pts on VDZ for IBD w/ develop new-onset enthesitis Is this true drug rxn or previously masked by prior meds (TNF)? Usually unilateral +/- oligo, dactylitis Most respond to NSAID or injxn, 27% change Rx

Eric Dein ericdeinmd ( View Tweet)

Enthesitis @lihi_eder @RheumNow #RNL2024 - NSAID - 1st line in mild/isolated - GC injxn but caution at Achilles - MTX cond rec by GRAPPA (SEAM PsA) - All bDMARD work vs PBO (TNFi, IL17, 12/23, 23, JAK, PDE4) - none superior - IL17 v ADA: higher resol for IXE v ADA, but mixed data https://t.co/20KnQo4kpq

Links:

Eric Dein ericdeinmd ( View Tweet)
Advanced therapies in enthesitis. Don't believe the spin, they all work, no clear evidence that any agent is better than others. @lihi_eder @RheumNow #RNL2024 https://t.co/FwLMUmmClB

Links:

Richard Conway RichardPAConway ( View Tweet)
@JointMD updates us on nomenclature. "AS" is out and "AxSpA" is in. #RNL2024 @RheumNow https://t.co/gdmZeuMNpW

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2024 @RheumNow @lihi_eder on enthesitis - ~1/3 PsA, SpA - Enthesitis precedes onset of PsA in PsO, high u/s score ass. w/ RFs (BMI, nail dyst) - Exam: tenderness (non-specific), as swelling uncommon. U/s helpful, but non-specif - Marker of severity, higher risk of damage

Eric Dein ericdeinmd ( View Tweet)

Dr. @lihi_eder recommends enthesial evaluation with POC ultrasound if available in addition to her clinical evaluation. #RNL2024 @RheumNow https://t.co/LQiyFK5VB1

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Goodbye AS. Eric Ruderman #RNL2024 @RheumNow https://t.co/FThKwuP3M6

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients. #RNL2024 @RheumNow https://t.co/bPLR7zpNe2

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Thank you to all of the excellent #RNL2024 speakers! @Bweber04, Dr. Monica Guma, Dr. Hani Gabalawy, Dr. Connie Weyand, Dr. Lisa Stamp, @AlexisOgdie, @_AprilArmstrong, @lihi_eder, @JointMD, Dr. Kevin Winthrop, Dr. Bruce Strober, @BharatKumarMD, Dr. David Karp, @Kahlenberglab,… https://t.co/f6gzCwe7Xb https://t.co/2SY9mPqdkO

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
"The best part of #RNL2024 is the audience gets to ask the experts alot of questions" - Dr. P Dara commented how lectures are short and the Q&A sessions are long, giving people enough time to ask tough questions and get answers. @rheumnow

TheDaoIndex KDAO2011 ( View Tweet)

AS v nr-AxSpA for TNFi - no diff in response @JointMD @RheumNow #RNL2024 ADA: ASAS20 AS 58%, nr-AxSpA 52%, ASAS40 AS 39%, nr 36% (ATLAS, ABILITY-1) ETN: ASAS 20 59%/52%, ASAS50/40 44%/33% in p3 AS study v EMBARK CZP: RAPID-AxSpA - no diff bw AS & nr-AxSpA response in same trial https://t.co/Rau2CDYbY4

Links:

Eric Dein ericdeinmd ( View Tweet)
The ultimate treatment goal in LN is long term preservation of kidney function. Summary of part 3 of @andreafava brilliant talk. #RNL2024 @RheumNow https://t.co/vwiAbWEmRh

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Very insightful talk on Vasculitis and pregnancy by Catherine Sims. Pregnancy compatible medications. Remission state. Checking antibodies ; risk of transmission, pregnancy and fetal morbidity. #RNL2024 @RheumNow https://t.co/81NAN1ulO5

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
×